POU class 2 homeobox associating factor 1Genealiases: BOB1 · OBF-1 · OBF1 · OCAB
Q-omics provides the consensus-scored POU2AF1 profile across patient tissues and cancer cell-line models. POU2AF1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, POU2AF1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, POU2AF1 RNA expression shows 15,473 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where POU2AF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU2AF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU2AF1 survival associations across molecular data types. POU2AF1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU2AF1 RNA expression–survival associations across cancer types. High POU2AF1 expression shows unfavorable associations in KICH, but favorable associations in HNSC, SKCM, LUAD, CESC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for POU2AF1 RNA expression.
This table summarizes POU2AF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for POU2AF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU2AF1 shows lower tumor expression in COAD, KICH and PRAD and higher tumor expression in LUAD, LUSC and KIRC. The COAD box plot shows higher POU2AF1 RNA expression in normal versus tumor tissue (log2 FC = −2.420, t-test p < 0.001).
This table shows molecular features associated with POU2AF1 in patient tissues and cancer cell lines. In patient samples, POU2AF1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POU2AF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
